thalidomide has been researched along with Idiopathic Parkinson Disease in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Marketed drugs for Parkinson's disease (PD) treat disease motor symptoms but are ineffective in stopping or slowing disease progression." | 1.72 | Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. ( Bernardini, R; Burgaletto, C; Cantarella, G; Carboni, E; Cardia, MC; Carta, AR; Casu, MA; Coroneo, V; De Simone, A; Ena, A; Etzi, M; Fusco, G; Greig, NH; Lai, F; Palmas, MF; Picci, L; Pisanu, A; Scerba, MT; Tweedie, D, 2022) |
| "Lenalidomide is a thalidomide derivative designed for reduced toxicity and increased immunomodulatory properties." | 1.42 | Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. ( Anderson, S; Mante, M; Masliah, E; Rockenstein, E; Valera, E, 2015) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palmas, MF | 1 |
| Ena, A | 1 |
| Burgaletto, C | 1 |
| Casu, MA | 1 |
| Cantarella, G | 1 |
| Carboni, E | 2 |
| Etzi, M | 1 |
| De Simone, A | 1 |
| Fusco, G | 1 |
| Cardia, MC | 1 |
| Lai, F | 1 |
| Picci, L | 1 |
| Tweedie, D | 2 |
| Scerba, MT | 2 |
| Coroneo, V | 1 |
| Bernardini, R | 1 |
| Greig, NH | 2 |
| Pisanu, A | 2 |
| Carta, AR | 2 |
| Boi, L | 1 |
| Mulas, G | 1 |
| Fenu, S | 1 |
| Spiga, S | 1 |
| Valera, E | 1 |
| Mante, M | 1 |
| Anderson, S | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Crystal, SC | 1 |
| Leonidas, J | 1 |
| Jakubowski, A | 1 |
| Di Rocco, A | 1 |
| Boireau, A | 1 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 1 |
5 other studies available for thalidomide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cytokines; Disease Models, Animal; Disease Progression; Drug Repositioning | 2022 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunol | 2019 |
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Line, Transformed; Cytokines; Disease Models, A | 2015 |
Thalidomide induced acute worsening of Parkinson's disease.
Topics: Aged; Humans; Immunosuppressive Agents; Male; Parkinson Disease; Primary Myelofibrosis; Thalidomide | 2009 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |